history of glp-1 drugs Oral Small-Molecule Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies Frontiers | GLP-1 receptor agonists:
Description
To provide context, GLP-1RAs comprise a heterogeneous class of incretin-based agents approved for the treatment of T2DM and, more recently, obesity
Anhedonia and Depression on GLP-1s Because GLP-1s dampen dopamine release, there is a risk of dopamine blunting. This happens when the body doesnt release enough dopamine and causes emotional flatness
Ambrosio, M
2025: FDA expanded indication oral semaglutide now approved to reduce major cardiovascular events (MACE) in adults with T2DM at high CV risk
